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Abstract
Background: A consensus on digital ulcer (DU) definition in systemic sclerosis (SSc) has been recently reached
(Suliman et al., J Scleroderma Relat Disord 2:115-20, 2017), while for their evaluation, classification and categorisation, it
is still missing. The aims of this study were to identify a set of essential items for digital ulcer (DU) evaluation, to
assess if the existing DU classification was useful and feasible in clinical practice and to investigate if the new
categorisation was preferred to the simple distinction of DU in recurrent and not recurrent, in patients with
systemic sclerosis (SSc).
Methods: DeSScipher is the largest European multicentre study on SSc. It consists of five observational trials (OTs)
, and one of them, OT1, is focused on DU management. The DeSScipher OT1 items on DU that reached ≥ 60% of
completion rate were administered to EUSTAR (European Scleroderma Trials and Research group) centres via online
survey. Questions about feasibility and usefulness of the existing DU classification (DU due to digital pitting scars, to
loss of tissue, derived from calcinosis and gangrene) and newly proposed categorisation (episodic, recurrent and
chronic) were also asked.
Results: A total of 84/148 (56.8%) EUSTAR centres completed the questionnaire. DeSScipher items scored by ≥ 70% of
the participants as essential and feasible for DU evaluation were the number of DU defined as a loss of tissue (level of
agreement 92%), recurrent DU (84%) and number of new DU (74%). For 65% of the centres, the proposed classification
of DU was considered useful and feasible in clinical practice. Moreover, 80% of the centres preferred the categorisation
of DU in episodic, recurrent and chronic to simple distinction in recurrent/not recurrent DU.
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Conclusions: For clinical practice, EUSTAR centres identified only three essential items for DU evaluation and
considered the proposed classification and categorisation as useful and feasible. The set of items needs to be validated
while further implementation of DU classification and categorisation is warranted.
Trial registration: Observational trial on DU (OT1) is one of the five trials of the DeSScipher project (ClinicalTrials.gov;
OT1 Identifier: NCT01836263, posted on April 19, 2013).
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Background
In systemic sclerosis (SSc), the pathophysiology is char-
acterised by immune, endothelial and fibroblast dysfunc-
tion [1] and microvascular involvement is one of the
most important features of the disease [2]. The evolution
of vessel involvement frequently leads to tissue ischemia
and formation of digital ulcers (DU) that are considered
as a significant clinical burden [3, 4] reducing patients’
quality of life [5]. In SSc, the compelling need for a pre-
cise definition [6] has eventually led to a consensus on
DU definition [7], while for their evaluation, classifica-
tion and categorisation, an overall agreement is still
missing [8].
Since different types of DU may occur in SSc, a DU
classification according to their main features into DU
associated digital pitting scars, DU associated with calci-
nosis, DU due to loss of tissue not associated with DPS
or calcinosis (Pure DU) (Fig. 1) and DU associated with
gangrene has been proposed [9]. Recently, a new cat-
egorisation of DU into episodic, recurrent and chronic
DU, derived from the analysis of more than 1400 pa-
tients in Europe, has been suggested [3].
DeSScipher is the largest European multicentre project
aimed to decipher the optimal management of SSc. It
consists of five observational trials (OTs) focusing on
DU (OT1), hand arthritis, interstitial lung disease, pul-
monary hypertension and heart disease.
The aims of this study were to identify in SSc a set of es-
sential items for DU evaluation in clinical practice, starting
from a large core of items contained in the OT1, to assess
if the existing DU classification was useful and feasible in
clinical practice and to investigate whether the DU cat-
egorisation was preferred to the simple classification of
DU (i.e. recurrent and not recurrent).
Methods
Observational trial on DU (OT1) is one of the five trials
of the DeSScipher project (ClinicalTrials.gov; OT1 Iden-
tifier: NCT01836263, April 19, 2013).
The DeSScipher project [10] was based on the use of
the EUSTAR (European Scleroderma Trials and Research
group) long-term databank MEDS (Minimal Essential
Data Set) accessible online [11]. The structure of the mul-
ticentre and international, prospective, longitudinal
EUSTAR database has been described previously [12].
In OT1, the efficacy of different vasoactive/vasodilating
drugs on DU prevention and healing was analysed consid-
ering a large number of clinical items on cutaneous lesions
of the upper and lower limbs. A tailored approach of DU
classification according to their main features was adopted:
DU associated digital pitting scars (DPS), DU associated
with calcinosis, DU due to loss of tissue not associated with
DPS or calcinosis (Pure DU) (Fig. 1) and DU associated
with gangrene [9]. Since recurrent DUs are a challenge in
clinical practice, these data were also collected in the OT1.
For the purpose of the DeSScipher observational trials,
the MEDS online database was extended and adapted ac-
cording to the needs of the individual projects. The
OT1-specific DeSScipher dataset included more than 30
supplementary clinical items in addition to three items on
upper limb lesions contained in the original MEDS online
database (digital ulcers, pitting scars on fingertips and
gangrene).
OT1 data on DU were collected prospectively from
April 2013 to November 2016. At the time of the ana-
lysis (November 2016), clinical data on 1749 patients en-
rolled into OT1 were stored in the database. Out of
the items contained in the database, only those on cutane-
ous lesions were selected. Clinical items on upper limb DU
Fig. 1 Pure DU due to loss of tissue not dependent from digital
pitting scar or calcinosis
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distal to the proximal interphalangeal joints (PIP) were then
identified and their completeness (completion rate) was
assessed. Completeness was defined as the proportion of
stored data against the potential of “100% complete” or the
extent to which data were not missing [13]. Items that
reached more than 60% of completeness (completion rate)
were identified and inserted in a questionnaire asking
which of the identified items were considered essential for
DU management in everyday clinical practice. Questions
about feasibility and usefulness of the DU classification
were adopted in OT1 and the newly proposed DU categor-
isation [3]. The new DU categorisation was defined as
follows:
– Episodic DU (rarely recurrent DU) defined as DU
detected only at one follow-up visit and absence of
DU at the remaining follow-up visits.
– Recurrent DU (frequently recurrent DU) defined as
DU detected at two or more follow-up visits and ab-
sence of DU on at least one follow-up visit.
– Chronic DU defined as one or more DU and/or new
DU detected at every follow-up visit.
This categorisation was published after the beginning of
the OT1 study and therefore could not originally be
adopted.
The questionnaire was administered to all EUSTAR
centres by online survey via SurveyMonkey commercial
software. The names of the EUSTAR co-workers are
provided in Additional file 1.
Ethical approval of DeSScipher OT1 had been ob-
tained from all participating centres’ local ethics com-
mittees (project coordinator’s ethics board: Ethics
Review board of the Justus-Liebig University Giessen,
Germany, approval no 02/13; partner centres’ ethics
review boards: University of Zurich, Switzerland; Uni-
versity of Paris, France; University of Florence Italy;
The Second University of Naples, Italy; University of
Basel, Switzerland; University College of London, UK;
University of Berlin Charité, Germany; University of
Pécs, Hungary; University of Leeds, UK; and contribu-
tor centres’ ethics boards (additional 21 centres)).
Each patient signed a written informed consent form.
Moreover, there was an external data monitoring as a
part of study quality control.
The assessment of the completion rate of different
clinical items included in the study was performed
by SPSS software, version 22. Responses to the on-
line questionnaire were analysed by the SurveyMon-
key commercial software.
Results
OT1 contained 35 clinical items on upper and lower
limb cutaneous lesions; 18 were on the upper limb DU
distal to PIP (Table 1). The items on upper limb DU dis-
tal to the PIP and their data completeness are shown in
italic letters in Table 1.
The survey on usefulness of the items that reached ≥
60% of completeness in the OT1 was concluded by a
total of 84/148 (56.8%) EUSTAR centres. The items that
obtained the highest score as essential and feasible for
DU evaluation in everyday clinical practice (Table 2)
were the following:
 Number of DU defined as due to loss of tissue (pure
ulcers) (level of agreement 92%)
 Recurrent DU (84%)
 Number of new DU (74%)
A significant number of centres (64%) agreed that the
DU classification adopted in OT1 [9] was useful to iden-
tify DU and their characteristics fundamental to shape
the management in everyday clinical practice. Concern-
ing the new categorisation of DU [3], 80% of the centres
preferred the distinction in episodic, recurrent and
chronic DU compared to the simple division in recur-
rent and not recurrent DU.
Discussion
This study introduces for the first time the concept of
essential clinical items for the evaluation and manage-
ment of DU in SSc. These essential items might become
a useful tool for physicians treating DU in everyday clin-
ical practice and may also become outcome measures to
be used in clinical trials.
The item considered as the most important for DU
management was the number of DU defined as a loss of
tissue, voted by more than 90% of participants. Thus,
the DU due to loss of tissue or pure DU, referring to a
DU occurring neither in association with DPS nor with
calcinosis, was considered as the most important form
of DU in SSc. This finding underlines the perceived im-
portance of the clinical burden of this type of DU, since
they usually represent the most severe type of DU where
vasoactive/vasodilating drugs used for DU treatment
have been tested. It is interesting to remark that the as-
sessment of other types of DU, as those due to DPS or
to calcinosis, was not evaluated as important in clinical
practice. This may likely reflect the fact that these le-
sions are usually considered mild and not disabling.
Recurrent DU and number of new DU were the sec-
ond and the third chosen essential items, respectively.
The number of new DU was considered more import-
ant than the number of healed DU. In fact, the DU oc-
currence has been correlated to a worse outcome and a
poor quality of life in large prospective SSc cohorts [4, 5,
14, 15]. The number of new DU was included by partici-
pants among the essential items, being probably
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considered as an indicator of clinical worsening and
more severe disease.
Unexpectedly, only 20% of centres considered the
number of healed DU useful and feasible for DU man-
agement in clinical practice as this was the least voted
item. This result may reflect a difficulty in assessing the
healing of each DU in clinical practice, since not always
all patients are seen at time interval useful to depict the
healing of all lesions.
Interestingly, only half of the participants chose DU
distal to the proximal interphalangeal joints as an im-
portant item. This indicates that not all clinicians con-
sidered the site of DU important for their management.
However, DUs located on the fingertips usually follow
tissue damage due to chronic ischaemia [14], while DUs
on other locations may also be due to cutaneous retrac-
tion and microtrauma, thus being less responsive to
vasodilating/vasoactive drugs.
Surprisingly, for less than 60% of the participants, the
presence of infection was essential for DU management.
This may indicate insufficient attention to this item even
by centres expert in SSc management. Accordingly,
there is a scarce number of scientific publications on in-
fectious complications of DU in SSc [3, 16, 17], and up
to now, no study has addressed the impact of infection
on DU healing. Data published till now indicate that in-
fection is frequent in patients with DU. Giuggioli et al.
observed in a retrospective study that 51% of 82 SSc pa-
tients with DU presented infected DU over a three-year
observational period [17]. Moreover, in the analysis of
Table 1 OT1 DeSScipher items and their data completeness
OT1 DeSScipher item Overall data
completeness (%)
Pitting scars fingertips 87.3
Digital ulcers 93.4
DU distal to the PIP 95.2
DU distal to the PIP: within last 24 weeks 34.6
DU distal to the PIP: intravenous Iloprost in last 3
months or present
44.7
DU distal to the PIP: recurrent 95.1
Upper limbs: total number of DU distal to the PIP 83.1
Upper limbs: history of DU distal to the PIP 91.3
Upper limbs: presence of infection of DU distal to
the PIP
96.6
Upperlimbs: gangrene 88.2
Upperlimbs: previous amputation 88.7
Upper limbs/localisation of DU PIP: fingertip 58.5
Upper limbs/localisation of DU PIP: on bony
prominence
31.8
Upper limbs/localisation of DU PIP: unknown 14.0
Upper limbs: number of DU defined as loss of
tissue
65.4
Upper limbs: number of DU due to calcinosis 66.0
Upper limbs: number of DU due to digital pitting
scars
60.7
Upper limbs: number DU with unknown origin 55.3
Upper limbs: number of new DU 83.1
Upper limbs: number of DU healed 76.7
Lower limbs: total number of DU 84.7
Lower limbs: history of DU 86.2
Lower limbs: presence infection of DU 80.2
Lower limbs: gangrene 87.8
Lower limbs: previous amputation 88.2
Lower limbs/localisation of DU: patella 1.0
Lower limbs/localisation of DU: malleoli 20.8
Lower limbs/localisation of DU: calcaneus 8.3
Lower limbs/localisation of DU: toes 45.9
Lower limbs/localisation of DU: any other part
of leg
14.6
Lower limbs/localisation of DU: unknown 6.2
Lower limbs: number of new DU 83.8
Lower limbs: number of DU healed 82.0
Lower limbs: peripheral arterial disease 86.8
Subcutaneous calcinosis hands 92.4
Data completeness of DeSScipher items on upper limb DU distal to PIP are in
italic letters
DU digital ulcers, PIP proximal interphalangeal joints
Table 2 Essential clinical items for DU assessment and
management
Item Level of agreement regarding feasibility
and usefulness of single items in clinical
practice (%)
Number of DU defined as
loss of tissue
91.7
Recurrent DU 83.9
Number of new DU 73.6
History of DU 60.9
Gangrene 60.9
Total number of DU 59.8
Infection of DU 58.6
DU distal to the proximal
interphalangeal joints
50.6
Previous amputation 49.4
Number of DU due to
calcinosis
46.4
Number of DU due to DPS 45.2
Number of healed DU 24.1
The items that reached level of agreement ≥ 70% are in italic letters
DU digital ulcers, DPS digital pitting scars
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1459 patients taking part of the large DUO registry, soft
tissue infection requiring systemic antibiotics has been
observed in 60% of patients with one or more DU at
every follow-up visit over 2 years [3]. In addition, it is a
common clinical observation that infected DUs have im-
paired healing potential in SSc, and it has been shown
that infected wounds and ulcers have a worse outcome
in other clinical settings [18].
It is of note that gangrene and previous amputation
were considered important for DU management only by
60% and 50% of centres, respectively. However, a recent
study on more than 4600 patients demonstrated that
gangrene is still a common event in current practice, oc-
curring in 18% of patients with SSc-related DU [19].
Recurrent DUs are a real clinical challenge in SSc. Ac-
cordingly, recurrent DU represented the second most
voted clinical item in our study. Simple distinction in re-
current and not recurrent DU may not fully depict the
level of DU-related disease burden. For this reason, a new
categorisation, based on the longitudinal pattern of DU re-
currence over the 2 years in the registry containing more
than 1400 patients across Europe has been recently pro-
posed [3]. The participating centres in our study have
recognised the importance of this categorisation, as more
than 80% of them agreed on its utility and feasibility in
clinical practice. In fact, it may help to identify patients
with more severe DU disease burden that may require
more intensive treatment, as already suggested [3].
The aim of the OT1 was to evaluate the best vasodilat-
ing/vasoactive therapy for DU prevention and healing
through observational non-interventional design. In
order to distinguish between different types of DU that
might have different response to the treatment, OT1
needed to classify DU. Since there is no universally ac-
cepted classification of DU in SSc, OT1 adopted the one
proposed by Amanzi et al. [9] based on observations ex-
trapolated from real life data on more than 1500 DU [9].
Our study has shown that this classification may be use-
ful and feasible in everyday clinical practice as indicated
by 64% of the participating centres.
The strength of this study is that the items were
already pre-selected based on the analysis of data avail-
ability in the DeSScipher project, the first prospective
multi-centric European study that expressly addressed
DU management in SSc, with a study population of
more than 1600 SSc patients. More than 80 expert cen-
tres in SSc management across the world were included
in this survey. The limitation of this project is that the
online survey was based on the opinion of a single ex-
pert of each individual centre. In addition, the survey
contained only clinical items (DU features assessed by
the clinical history and/or simple clinical examination).
Several laboratory and instrumental items have been col-
lected in the OT1 database. The importance of some of
these parameters for DU management, such as capillaro-
scopic findings shown to be risk factors for DU occur-
rence [20, 21], should be addressed in the future.
Our findings now need prospective validation using
data-driven approach on large SSc cohorts in order to
confirm the real usefulness of these essential items and
the role of the proposed DU classification and categor-
isation in real-life clinical practice.
Conclusions
For clinical practice, DeSScipher/EUSTAR centres iden-
tified only three essential items for DU evaluation. They
considered the proposed classification and categorisation
of DU as useful and feasible. The set of items needs to
be further validated while further implementation of DU
classification and categorisation is warranted.
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